---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-000966"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T04:15:53.260351+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical reports exenatide implant cuts liver fat 82% in obese mice

## Summary
- Exenatide implant reduced liver fat by 82% vs sham in high-fat diet obese mice after 12 weeks (Oil Red O staining).
- Exenatide delivered via NanoPortal technology showed durable body weight reduction in rats over 105-140 days.
- Findings from corporate slide presentation furnished as Exhibit 99.1; no material financial updates.
- Vivani is developing NPM-119 (exenatide implant) for metabolic indications.

## SEC filing metadata
- accession: 0001753926-25-000966
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392625000966/0001753926-25-000966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392625000966/vani-20250617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-000966
- JSON: https://secwatch.observer/filing/0001753926-25-000966.json
- Plain text: https://secwatch.observer/filing/0001753926-25-000966.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.